Shanghai Henlius Biotech IPO: Cash Breakeven Analysis
Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...
662 Views
Shanghai Henlius (复宏汉霖) IPO: Thoughts on Valuation
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In our previous insights covering Shanghai Henlius, we have...
734 Views
Shanghai Henlius Biotech IPO Initiation: Going Large
Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...
840 Views
Shanghai Henlius (复宏汉霖) IPO: What's New in the Re-Filed Prospectus?
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. Shortly after its previous application lapsed, the company refiled...
848 Views
Hansoh Pharma IPO: Valuation Reasonable for the Trade-Offs
Hansoh Pharmaceutical (3692 HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. It announced its IPO price range of...
830 Views